Highlights Newsletter 4
This newsletter presents you the Best-read key sessions:
1. Podcast with Dr. Ahmed about real-world outcomes of brexucabtagene autoleucel for relapsed or refractory
mantle cell lymphoma
2. Benefit of ide-cel versus standard regimens maintained across patient populations with high-risk
relapsed/refractory multiple myeloma
3. Epcoritamab with rituximab plus lenalidomide provides durable responses in patients with high-risk follicular
lymphoma, regardless of POD24 status
4. Navigating secondary acute myeloid leukaemia in 2023
5. Imetelstat effective in heavily transfusion-dependent patients with lower-risk myelodysplastic syndrome